| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
54,451 |
50,905 |
$9.35M |
| S9083 |
Global fee urgent care centers |
38,116 |
30,562 |
$4.36M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
34,590 |
31,902 |
$176K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
10,768 |
10,444 |
$106K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
9,944 |
9,361 |
$72K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,018 |
1,005 |
$38K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,798 |
1,742 |
$34K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
8,024 |
7,372 |
$18K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
3,318 |
3,095 |
$8K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
2,780 |
2,711 |
$7K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
5,425 |
4,913 |
$5K |
| 0001A |
|
436 |
377 |
$3K |
| 0011A |
|
179 |
150 |
$1K |
| 0002A |
|
267 |
233 |
$880.00 |
| 0031A |
|
95 |
83 |
$640.00 |
| 99443 |
|
742 |
727 |
$636.70 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
1,009 |
951 |
$519.00 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
490 |
466 |
$314.46 |
| 81025 |
|
10,604 |
10,130 |
$309.56 |
| 0071A |
|
107 |
96 |
$280.00 |
| 96127 |
|
4,144 |
3,800 |
$256.98 |
| 0012A |
|
118 |
100 |
$240.00 |
| 86580 |
|
5,465 |
4,966 |
$183.79 |
| 99384 |
|
169 |
168 |
$81.00 |
| 36415 |
Collection of venous blood by venipuncture |
1,338 |
1,305 |
$66.62 |
| 81002 |
|
1,607 |
1,541 |
$42.81 |
| 0064A |
|
14 |
12 |
$40.00 |
| 0052A |
|
26 |
23 |
$40.00 |
| 0072A |
|
34 |
33 |
$40.00 |
| 99499 |
|
174 |
154 |
$40.00 |
| 0004A |
|
30 |
27 |
$40.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,328 |
1,309 |
$38.80 |
| 3725F |
|
2,110 |
1,990 |
$30.00 |
| 81003 |
|
1,855 |
1,781 |
$25.29 |
| 90716 |
|
68 |
59 |
$20.00 |
| 90715 |
|
218 |
213 |
$10.00 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
365 |
356 |
$6.30 |
| 99401 |
|
364 |
318 |
$1.08 |
| 99201 |
|
120 |
108 |
$0.07 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
491 |
466 |
$0.03 |
| 99385 |
|
93 |
83 |
$0.02 |
| 91305 |
|
96 |
87 |
$0.00 |
| 99070 |
|
92 |
91 |
$0.00 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,327 |
1,308 |
$0.00 |
| 3351F |
|
1,850 |
1,748 |
$0.00 |
| 91301 |
|
225 |
181 |
$0.00 |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
381 |
371 |
$0.00 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
49 |
49 |
$0.00 |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
1,288 |
1,248 |
$0.00 |
| 59430 |
|
54 |
48 |
$0.00 |
| 91303 |
|
48 |
44 |
$0.00 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
400 |
386 |
$0.00 |
| 86592 |
|
320 |
314 |
$0.00 |
| 87088 |
|
12 |
12 |
$0.00 |
| 82607 |
|
13 |
13 |
$0.00 |
| 99000 |
|
384 |
344 |
$0.00 |
| 80051 |
|
24 |
24 |
$0.00 |
| 99429 |
|
49 |
43 |
$0.00 |
| 82746 |
|
13 |
13 |
$0.00 |
| 84443 |
Thyroid stimulating hormone (TSH) |
29 |
29 |
$0.00 |
| 81000 |
|
12 |
12 |
$0.00 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
53 |
53 |
$0.00 |
| 91307 |
|
74 |
62 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
25 |
24 |
$0.00 |
| 0051A |
|
17 |
17 |
$0.00 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
29 |
29 |
$0.00 |
| 87490 |
|
14 |
14 |
$0.00 |
| 87590 |
|
14 |
14 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
20 |
15 |
$0.00 |
| 91300 |
|
499 |
425 |
$0.00 |
| 99173 |
|
1,366 |
1,313 |
$0.00 |
| 87799 |
|
86 |
84 |
$0.00 |
| 80061 |
Lipid panel |
45 |
45 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
727 |
602 |
$0.00 |
| 87481 |
|
163 |
160 |
$0.00 |
| 90713 |
|
34 |
31 |
$0.00 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
412 |
408 |
$0.00 |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
78 |
77 |
$0.00 |
| 82565 |
|
24 |
24 |
$0.00 |
| 87512 |
|
98 |
96 |
$0.00 |
| 90461 |
|
540 |
416 |
$0.00 |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
29 |
29 |
$0.00 |
| 99442 |
|
52 |
51 |
$0.00 |
| G9357 |
Post-partum screenings, evaluations and education performed |
49 |
43 |
$0.00 |
| 90707 |
|
13 |
12 |
$0.00 |
| 82947 |
|
24 |
24 |
$0.00 |
| 84520 |
|
24 |
24 |
$0.00 |
| 90734 |
|
150 |
144 |
$0.00 |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
13 |
13 |
$0.00 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
42 |
21 |
$0.00 |